Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Acerand Therapeutics Reports ...
Acerand Therapeutics Reports Promising Clinical Activity and Favorable Safety Profile for ACE-106, a Potential Best-in-Class PARP1 Selective Inhibitor SHANGHAI & INDIANAPOLIS--(BUSINESS WIRE)--Acerand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results